Clinical efficacy of TanCAR7 T cells in patients with r/rNHL. (A) Durations of the response and survival after the infusion of TanCAR7 T cells. Patient 3 died of severe pneumonia outside of our institute after achieving a CR 10 months postinfusion, and patient 18 died from a severe pulmonary infection associated with persistent unrecoverable myelosuppression. Four patients had new lesions in the context of controlled primary lesions. (B) Objective response rate (ORR) among the 28 treated patients; it was calculated by dividing the number of patients with a CR or PR by the number of the patients who received TanCAR7 T cells. Kaplan-Meier estimates of progression-free survival (C) and overall survival (D). The rates were calculated using data for all 28 patients who received an infusion. ALL, acute lymphocytic leukemia; NE, not evaluated; PR, partial response.